Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Study shows benefits of therapeutic filtration devices for colorectal cancer treament

Aethlon Medical : 21 December, 2010  (Company News)
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, is demonstrating the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
In the lymphoma study, conducted at the City of Hope Cancer Research Hospital in California, exosomes derived from lymphoma patients were circulated through Aethlon Medical's Hemopurifier. Each sample confirmed significant exosome capture rate validating that the company's Hemopurifier is a candidate therapy to address lymphoma.

In a separate study, exosomes derived from colorectal cancer patients were also circulated through the company's Hemopurifier. The results for the colorectal study also confirmed significant exosome capture rate and the prospect of applying the Hemopurifier as a therapeutic for this type of cancer. The company anticipates providing additional details of these studies in a forthcoming report.

Additionally, as previously announced, Exosome Sciences, a wholly owned subsidiary of Aethlon Medical, is developing its proprietary ELLSA Assay that will allow researchers to detect exosomes in blood and other fluids. These studies further validate the company's detection Assay in identifying lymphoma and colorectal cancer derived from cancer-released exosomes. As a result, this diagnostic tool offers the potential to improve lymphoma and colorectal cancer diagnosis and monitor disease progression.

The Hemopurifier is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Lymphoma is a cancer in the lymphatic of the immune system and presents as a liquid tumor of lymphoid cells. According to the Leukemia and Lymphoma Society, an estimated 21,530 persons will die of lymphoma in the United States in 2010

Colorectal cancer, also called colon cancer or large bowel cancer, includes cancerous growths in the colon, rectum and appendix. With 655,000 deaths worldwide per year, it is the fourth most common form of cancer in the United States and the third leading cause of cancer-related death in the Western world.

'Our goal is to provide oncologists with an adjunct therapeutic device that will improve treatment of lymphoma and colorectal cancer without adding drug toxicity or interaction risks,' said , Jim Joyce, Aethlon Medical's Chairman and Chief Executive Officer. 'The data also provides supporting evidence that our Hemopurifier has broad-spectrum applications against various forms of cancer.' Aethlon previously demonstrated that its Hemopurifier successfully captured exosomes derived from ovarian, breast and melanoma cancer patients during in vitro studies.

Aethlon believes the Hemopurifier represents the sole therapeutic strategy to directly inhibit or reverse the deleterious effects associated with exosomes secreted by tumours as a survival mechanism for cancer. Tumour-secreted exosomes have been reported to trigger programmed cell death (apoptosis) of immune cells; interrupt T-cell signaling required to mount an immune response; inhibit the production of anti-cancer cytokines, and have implications in the spread of metastasis and allowing for angiogenesis.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo